ERBB2-positive metastatic breast cancer benefits from endocrine therapy. Explore personalized regimens for improved patient outcomes. Read more on potential clinical implications.
First-line regimens with endocrine therapy (ET) may be associated with benefits among patients with human epidermal growth factor receptor 2-positive (ERBB2-positive [formerly HER2-positive]) metastatic breast cancer (MBC), according to a study published online in JAMA Network Open.
Marcela Carausu, M.D., from Institut Curie in Saint-Cloud, France, and colleagues evaluated the association of hormone receptor status and first-line inclusion of ET with outcomes among patients with ERBB2-positive MBC. The analysis used clinical data from the French clinical Epidemiological Strategy and Medical Economics cohort of 4,145 patients who started treatment between 2008 and 2017 with follow-up through June 18, 2020.
The researchers observed no significant difference in overall or progression-free survival for 1,520 patients treated with ERBB2-targeted therapy with chemotherapy and with or without ET versus 203 patients receiving ERBB2-targeted therapy with ET. Findings were seen regardless of type of ERBB2-targeted therapy (trastuzumab or trastuzumab with pertuzumab). In propensity-matched patients, results were similar. Among patients with ERBB2-targeted therapy with chemotherapy, those with maintenance ET had significantly better progression-free (hazard ratio, 0.70) and overall survival (hazard ratio, 0.47).
“Our findings suggest that ET-containing regimens may be associated with benefits for a subgroup of patients, suggesting that results from randomized clinical trials investigating a more personalized approach for these patients may be relevant and necessary,” the authors write.
By subscribing, you consent to receive emails from BlackDoctor.pro You may unsubscribe at any time. Privacy Policy & Terms of Service.
Are you a healthcare professional? Register with us today!